170 related articles for article (PubMed ID: 27434957)
1. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.
Dmitriev AA; Rosenberg EE; Krasnov GS; Gerashchenko GV; Gordiyuk VV; Pavlova TV; Kudryavtseva AV; Beniaminov AD; Belova AA; Bondarenko YN; Danilets RO; Glukhov AI; Kondratov AG; Alexeyenko A; Alekseev BY; Klein G; Senchenko VN; Kashuba VI
Dis Markers; 2015; 2015():241301. PubMed ID: 26491211
[TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays.
Dmitriev AA; Kashuba VI; Haraldson K; Senchenko VN; Pavlova TV; Kudryavtseva AV; Anedchenko EA; Krasnov GS; Pronina IV; Loginov VI; Kondratieva TT; Kazubskaya TP; Braga EA; Yenamandra SP; Ignatjev I; Ernberg I; Klein G; Lerman MI; Zabarovsky ER
Epigenetics; 2012 May; 7(5):502-13. PubMed ID: 22491060
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
5. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
6. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
7. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
8. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
9. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer.
Senchenko VN; Kisseljova NP; Ivanova TA; Dmitriev AA; Krasnov GS; Kudryavtseva AV; Panasenko GV; Tsitrin EB; Lerman MI; Kisseljov FL; Kashuba VI; Zabarovsky ER
Epigenetics; 2013 Apr; 8(4):409-20. PubMed ID: 23478628
[TBL] [Abstract][Full Text] [Related]
10. Altered methylation of multiple genes in carcinogenesis of the prostate.
Yamanaka M; Watanabe M; Yamada Y; Takagi A; Murata T; Takahashi H; Suzuki H; Ito H; Tsukino H; Katoh T; Sugimura Y; Shiraishi T
Int J Cancer; 2003 Sep; 106(3):382-7. PubMed ID: 12845678
[TBL] [Abstract][Full Text] [Related]
11. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
12. Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer.
Hashad DI; Hashad MM; Talaat IM; Ibrahim MA
Genet Test Mol Biomarkers; 2011 Oct; 15(10):667-70. PubMed ID: 21631298
[TBL] [Abstract][Full Text] [Related]
13. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
Urologiia; 2001; (2):37-40. PubMed ID: 11490716
[TBL] [Abstract][Full Text] [Related]
14. [Low-stage prostatic adenocarcinoma and atypical lesions of the prostate].
Maganto Pavón E; García González R; Ruiz Zárate C; Fernández González I; Fernández Fernández A; Vallejo Herrador J; Mateos Torres A; Escudero Barrilero A
Arch Esp Urol; 1990; 43(9):967-70. PubMed ID: 1708979
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males.
Ahmed MI; Abd-Elmotelib F; Farag RM; Ziada NA; Khalifa A
Clin Biochem; 1999 Aug; 32(6):439-45. PubMed ID: 10667479
[TBL] [Abstract][Full Text] [Related]
17. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
[TBL] [Abstract][Full Text] [Related]
19. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
Landers KA; Burger MJ; Tebay MA; Purdie DM; Scells B; Samaratunga H; Lavin MF; Gardiner RA
Int J Cancer; 2005 May; 114(6):950-6. PubMed ID: 15609297
[TBL] [Abstract][Full Text] [Related]
20. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
